证券代码：688393 证券简称：安必平 公告编号：2026-010 广州安必平医药科技股份有限公司 关于变更项目合伙人及签字会计师的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广州安必平医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日 召开第四届董事会第七次会议及第四届监事会第六次会议，于 2025 年 5 月 15 日召 开 2024 年年度股东大会，审议通过《关于续聘会计师事务所的议案》，同意聘任中 汇会计师事务所（特殊普通合伙）（以下简称"中汇会计师事务所"）为公司 2025 年度财务报表审计机构及内部控制审计机构。具体内容详见公司于 2025 年 4 月 22 日在上海证券交易所网站（www.sse.com.cn）披露的《关于续聘会计师事务所的公 告》（公告编号：2025-014）。 近日，公司收到中汇会计师事务所送达的《关于变更签字会计师的告知函》， 现将相关变更情况告知如下： 一、 本次签字会计师变更的基本情况 中汇会计师事务所为公司 2025 年度财务报表和内部控制的审计 ...

一、本次会计政策变更概述 2024 年 12 月 6 日，财政部发布了《企业会计准则解释第 18 号》（财会〔2024〕 24 号），对"关于浮动收费法下作为基础项目持有的投资性房地产的后续计量" 和"关于不属于单项履约义务的保证类质量保证的会计处理"等方面内容进行规 范及明确,该解释自印发之日起施行，允许企业自发布年度提前执行。 二、本次会计政策变更的主要内容及对公司的影响 证券代码：688393 证券简称：安必平 公告编号：2026-009 广州安必平医药科技股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次会计政策变更系广州安必平医药科技股份有限公司（以下简称 "公司"）根据中华人民共和国财政部（以下简称"财政部"）发布的《企业会 计准则解释第 18 号》进行的相应变更，符合相关法律法规的规定和公司实际情 况，不涉及对公司以前年度的追溯调整，不会对公司已披露的财务报表产生影响， 对公司财务状况、经营成果和现金流量不会产生重大影响，亦不存在损害公司及 股东利益的 ...

证券代码：688393 证券简称：安必平 公告编号：2026-008 一、 医疗器械注册证的具体情况 | 胞学病理医师。 | | --- | 二、 对公司的影响 公司深耕病理诊断领域，经过多年研发积累，现已开发出涵盖"细胞学试剂 +制片设备+扫描仪+辅助判读"的宫颈癌检测智能化整体解决方案。宫颈细胞数 字病理图像辅助诊断软件由中国医学科学院北京协和医学院牵头，联合全国多家 权威医疗机构开展临床研究，相关研究成果于 2025 年 4 月发表在国际顶级期刊 《Nature Communications》。测试结果显示病理医生在软件辅助下阅片效率和诊 断灵敏度有明显提升。该注册证的取得，标志着公司在病理数智化转型领域实现 了从研发创新到市场化、规范化应用的关键跨越。 三、 风险提示 上述产品获证后的实际销售情况取决于市场的推广效果，未来业绩取决于国 内市场拓展力度、品牌综合影响力及市场实际需求等因素。敬请广大投资者谨慎 投资，注意投资风险。 特此公告。 广州安必平医药科技股份有限公司 关于自愿披露宫颈细胞数字病理图像辅助诊断软件 取得三类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 ...

广州安必平医药科技股份有限公司 关于预计 2026 年度日常关联交易额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否需要提交股东会审议：否 证券代码：688393 证券简称：安必平 公告编号：2026-007 广州安必平医药科技股份有限公司（以下简称"公司"）于 2026 年 3 月 26 日召开第四届董事会第十二次会议，审议通过了《关于预计 2026 年度日常关联 交易额度的议案》，本次日常关联交易预计金额合计为 1,996.65 万元人民币。出 席会议的非关联董事一致同意该议案，审议程序符合相关法律法规的规定。本次 日常关联交易额度预计事项无需提交股东会审议。 公司已于 2026 年 3 月 23 日召开了第四届独立董事专门会议第八次会议，审 议通过了《关于预计 2026 年度日常关联交易额度的议案》，并经公司全体独立董 事一致同意，形成以下意见：公司在 2026 年与关联方已经发生的关联交易及预 计将要发生的关联交易均为公司正常经营业务所需，属正常商业行为，遵循公平、 公正的原则，定价公允 ...

一、审议通过《关于预计 2026 年度日常关联交易额度的议案》 公司在 2026 年与关联方已经发生的关联交易及预计将要发生的关联交易均 为公司正常经营业务所需，属正常商业行为，遵循公平、公正的原则，定价公允 合理，符合有关法律、法规、规范性文件和《公司章程》等相关规定，不存在损 害公司和股东利益，特别是中小股东利益的情况，同意将该议案提交公司董事会 审议。 广州安必平医药科技股份有限公司 广州安必平医药科技股份有限公司 第四届董事会独立董事专门会议第八次会议决议 广州安必平医药科技股份有限公司（以下简称"公司"）第四届董事会独 立董事专门会议第八次会议于 2026 年 3 月 23 日（星期一）在公司 A102 会议室 以现场结合通讯的方式召开。会议通知已于 2026 年 3 月 20 日通过邮件的方式送 达各位独立董事。本次会议应出席独立董事 3 人，实际出席独立董事 3 人。 会议由吴翔主持，会议召开符合有关法律、法规、规章和《公司章程》的 规定。经各位独立董事认真审议，会议形成了如下决议： 表决结果：3 票同意，0 票反对，0 票弃权。 独立董事：吴翔、彭文平、吴红日 2026 年 3 月 23 日 ...

Core Viewpoint - Anbipin (688393.SH) reported a significant decline in its 2025 annual performance, with total operating revenue of 347 million yuan, a year-on-year decrease of 26.24%, and a net profit loss of 44.97 million yuan, shifting from profit to loss [1] Group 1: Financial Performance - The total operating revenue for 2025 was 347 million yuan, reflecting a 26.24% year-on-year decline [1] - The net profit attributable to the parent company was a loss of 44.97 million yuan, indicating a shift from profit to loss compared to the previous year [1] Group 2: Business Impact Factors - The implementation of national centralized procurement policies led to a significant price drop in the company's HPV product line, resulting in a revenue decrease of approximately 46.5 million yuan [1] - The company proactively optimized its business structure by focusing on the expansion of core business revenue and reducing the scale of agency product business [1] Group 3: Strategic Adjustments - To accelerate market penetration, the company actively adjusted its channel strategy, increasing the proportion of distribution channels [1] - The sales price of products decreased year-on-year, which had a short-term impact on overall gross profit [1]

Core Viewpoint - Anbiping (688393.SH) reported a significant decline in revenue and a shift to net loss for the fiscal year 2025, primarily due to the implementation of national procurement policies affecting product pricing and sales [1] Financial Performance - The total operating revenue for 2025 was 347 million yuan, representing a year-on-year decrease of 26.24% [1] - The net profit attributable to the parent company was a loss of 44.97 million yuan, a shift from profit to loss compared to the previous year [1] Business Impact - The HPV product line experienced a substantial price drop, leading to a revenue reduction of approximately 46.5 million yuan [1] - The company proactively optimized its business structure by focusing on core business revenue expansion and reducing the scale of agency product operations [1] Strategic Adjustments - To enhance market penetration, the company actively adjusted its channel strategy, increasing the proportion of distribution channels [1] - The sales price of products decreased year-on-year, which had a short-term negative impact on overall gross profit [1]

Group 1 - The core viewpoint of the article is that Anbiping reported a significant decline in revenue for the year 2025, with total operating income reaching 347.27 million yuan, representing a year-on-year decrease of 26.24% [2]

Core Viewpoint - Anping (688393.SH) reported a significant decline in its 2025 annual performance, with a focus on optimizing its business structure and adjusting channel strategies to enhance market penetration [1] Financial Performance - The company achieved an operating revenue of 347.27 million yuan, a year-on-year decrease of 26.24% [1] - The net profit attributable to the parent company was -44.97 million yuan, reflecting a year-on-year decline of 311.22% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -65.90 million yuan, showing a year-on-year decrease of 562.30% [1] Business Strategy - The company actively optimized its business structure by focusing on the expansion of its main business revenue and correspondingly reducing the scale of its agency product business [1] - To accelerate market penetration, the company is promoting adjustments in its channel strategy, increasing the proportion of distribution channels [1] - The average selling price of products has decreased year-on-year, which has had a short-term impact on overall gross profit [1]

Financial Performance - Total revenue for 2025 was CNY 347.27 million, a decrease of 26.24% compared to the previous year[3] - Net profit attributable to shareholders was CNY -44.97 million, a decline of 311.22% year-on-year[3] - The company reported a net profit of CNY -65.90 million after deducting non-recurring gains and losses, a decrease of 562.30% compared to the previous year[3] - Basic earnings per share were CNY -0.48, down 308.70% from CNY 0.23 in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,290.87 million, a decrease of 5.27% from the beginning of the period[5] - Shareholders' equity attributable to the parent company was CNY 1,190.04 million, down 5.23% from the beginning of the period[5] Revenue Impact Factors - The decline in revenue was significantly impacted by the national centralized procurement policy, leading to a revenue drop of approximately CNY 46.50 million from the HPV product line[6] - The company is focusing on optimizing its business structure and expanding distribution channels, which has temporarily affected overall gross margins[6] Future Outlook - Increased operational costs due to ongoing product research and development efforts in the fields of digital pathology and tumor companion diagnostics are expected to support long-term sustainable growth[6] - Investors are advised to note that the financial data presented is preliminary and unaudited, with final figures to be confirmed in the audited annual report[8]